- Home
- ETON vs BCAB Comparison
ETON vs BCAB Comparison
Compare ETON & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- BCAB
- Stock Information
- Founded
- ETON 2017
- BCAB 2007
- Country
- ETON United States
- BCAB United States
- Employees
- ETON N/A
- BCAB N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ETON Health Care
- BCAB Health Care
- Exchange
- ETON Nasdaq
- BCAB Nasdaq
- Market Cap
- ETON 199.5M
- BCAB 96.2M
- IPO Year
- ETON 2018
- BCAB 2020
- Fundamental
- Price
- ETON $8.82
- BCAB $2.08
- Analyst Decision
- ETON Strong Buy
- BCAB Strong Buy
- Analyst Count
- ETON 3
- BCAB 2
- Target Price
- ETON $12.00
- BCAB $6.00
- AVG Volume (30 Days)
- ETON 214.1K
- BCAB 1.6M
- Earning Date
- ETON 11-11-2024
- BCAB 11-08-2024
- Dividend Yield
- ETON N/A
- BCAB N/A
- EPS Growth
- ETON N/A
- BCAB N/A
- EPS
- ETON N/A
- BCAB N/A
- Revenue
- ETON $31,381,000.00
- BCAB N/A
- Revenue This Year
- ETON $19.61
- BCAB N/A
- Revenue Next Year
- ETON $35.39
- BCAB N/A
- P/E Ratio
- ETON N/A
- BCAB N/A
- Revenue Growth
- ETON 8.14
- BCAB N/A
- 52 Week Low
- ETON $3.03
- BCAB $1.14
- 52 Week High
- ETON $8.66
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- ETON 76.07
- BCAB 55.80
- Support Level
- ETON $7.58
- BCAB $1.87
- Resistance Level
- ETON $8.66
- BCAB $2.13
- Average True Range (ATR)
- ETON 0.42
- BCAB 0.12
- MACD
- ETON -0.07
- BCAB 0.00
- Stochastic Oscillator
- ETON 91.49
- BCAB 68.90
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.